
Available online at www.sciencedirect.com

SCIENCE DIRECT®

ELSEVIER

Comparative Biochemistry and Physiology, Part A 144 (2006) 306–315

CBP

www.elsevier.com/locate/cbpa

Review

Integration of membrane and nuclear estrogen receptor signaling☆

Dapeng Zhang, Vance L. Trudeau*

Department of Biology, University of Ottawa, Ottawa, Ontario, Canada

Received 30 September 2005; received in revised form 12 January 2006; accepted 18 January 2006

Available online 3 March 2006

---

### Abstract

The classical mechanism of estradiol (E2) action is mediated by the nuclear estrogen receptors ERα and ERβ, which function as ligand-dependent transcription factors that regulate transcription of target genes containing the consensus estrogen response element (ERE) in their promoter regions. However, accumulating evidence indicates that E2 can also exert its actions through a unique membrane estrogen receptor (mER). Upon activation of the mER, various signaling pathways (i.e. Ca²⁺, cAMP, protein kinase cascades) are rapidly activated and ultimately influence downstream transcription factors. Some target genes of the mER pathway may be activated independently of the nuclear estrogen receptor (nER). Additionally, it has been shown that classical nER action can be modulated by mER-initiated signaling through phosphorylation of nER and its coactivators, and by induction of third messengers (i.e. cyclin D1 and c-fos). Based on current evidence, we propose a model for E2 action integrating distinct membrane receptor and nuclear receptor signaling. This membrane receptor–nuclear receptor interaction is likely to exist for other hormones. Steroid hormones and other hormones acting through hormone receptors in the steroid receptor superfamily (i.e. thyroid hormones) also activate many of the same intracellular signaling cascades, which provides the basis for extensive crosstalk networks between hormones. The model proposed serves as a framework to investigate the diverse actions of hormones and endocrine disrupting chemicals (EDCs).

© 2006 Elsevier Inc. All rights reserved.

---

### Keywords: Estradiol; Membrane receptor; Nuclear receptor; Signaling; Gene regulation; Hormone crosstalk

---

### Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
D. Zhang, V.L. Trudeau / Comparative Biochemistry and Physiology, Part A 144 (2006) 306–315

1. Introduction

The main estrogenic hormone, 17β-estradiol (E2), is synthesized by aromatization of testosterone (Bulun et al., 2000). It plays important regulatory roles in a wide variety of biological processes including reproduction, differentiation, cell proliferation, apoptosis, inflammation, metabolism, homeostasis and brain function (Tsai and O’Malley, 1994). The primary mechanism of E2 action is mediated by transcriptional actions of the nuclear estrogen receptors, ERα and ERβ. Upon binding with a ligand, ERα and ERβ in the nucleus are released from inactive complexes containing heat-shock proteins and immunophilins (Ylikomi et al., 1998), homodimerize or heterodimerize (Cowley et al., 1997), and bind to a specific DNA estrogen response element (ERE) located in the promoters of target genes. In turn, DNA-bound ERs modulate target gene expression by interacting with a series of coactivators. In addition to direct binding to the ERE, nuclear estrogen receptor (nER) can affect gene expression through protein–protein interaction with other classes of transcriptional factors, such as AP-1 (Gaub et al., 1990) or Sp-1 (Castro-Rivera et al., 2001).

In contrast with classical nER action, the discovery of the rapid biochemical and physiological effects of E2 indicates the existence of novel mER-mediated actions. In this process, various protein kinase cascades, including mitogen activated protein kinase (MAPK), protein kinase A (PKA), protein kinase C (PKC), and phosphatidylinositol 3-OH kinase (PI3K) are activated after a short exposure time (seconds to minutes) to E2. In addition, the classical ERα is present and can also signal from the level of plasma membrane in rat pituitary tumor cell line (Pappas et al., 1995; Norfleet et al., 1999). Very recently two laboratories have shown that a G-protein-coupled receptor (GPCR30) can act as a distinct mER in human SKBR3 breast tumor cell line (Thomas et al., 2005; Revankar et al., 2005).

Since rapid signaling cascades can ultimately influence the phosphorylation state of downstream transcription factors, induction of membrane receptor-mediated action provides an alternative way for E2 to regulate gene expression. Moreover, signaling pathways activated following binding of E2 to mER can influence nER-dependent transcription. Here we will review the existing data and propose a dynamic model of E2 action that integrates both mER and nER actions. Furthermore, such a model may be extended to the action of other hormones, and the molecular mechanism of hormone crosstalk between E2 and other hormones is discussed.

2. Nuclear receptor mediated action of E2: the classical mechanism

Nuclear actions of E2 are mediated by two main nuclear estrogen receptor subtypes, ERα and ERβ, which are members of a superfamily of nuclear receptors that function as ligand- or hormone-dependent transcription factors (McKenna and O’Malley, 2002). Two important functional domains in ERα and ERβ, the DNA binding domain (DBD) and the ligand binding domain (LBD), are well conserved both at the amino acid sequence and the structural levels, whereas there is considerable divergence in the N-terminus between receptor subtypes. Comparative aspects of nER structure and function in various species have been discussed previously and will not be considered here (Martyniuk et al., in press; Menuet et al., 2002; Thornton et al., 2003). The two major nER subtypes have distinct expressions patterns in tissues (Couse et al., 1997; Shughrue et al., 1997, 1998) and ER knockout mice models (αERKO and βERKO) exhibit different phenotypes (Couse and Korach, 2001; Hess, 2003; Hewitt et al., 2005) indicating distinct biological functions of the receptors. In contrast to the functional deficiencies in the reproductive system in both sexes of αERKO mice, male βERKO mice are fertile while females are subfertile.

The efficient transcriptional activity of nER requires recruitment of other transcription factors and multiple coactivators including SRC-1 (steroid receptor coactivator-1), GRIP-1 (glucocorticoid receptor-interacting protein-1), AIB1 (amplified in breast cancer 1), CBP/p300 (cAMP response element binding protein), PGC-1 (peroxisome proliferators-activated receptor gamma coactivator 1α) and p68 RNA helicase (McKenna and O’Malley, 2002; Metivier et al., 2003). Therefore, the availability of coactivators can greatly influence nER action. For example, in rodent brain reduction of SRC-1 and CBP protein with antisense oligonucleotides disrupted nER-mediated induction of progestin receptor gene (Molenda et al., 2002). In male Japanese quail, inhibition of SRC-1 significantly affected the estrogen-dependent male-typical sexual behavior, and is correlated with reduction in the volume of the preoptic medial nucleus and the expression of aromatase and vasotocin proteins (Charlier et al., 2005). Moreover, the transcription factor FoxA1, whose expression was induced via the nER, was found to be necessary for further nER action in human MCF-7 cancer cells (Laganiere et al., 2005; Carroll et al., 2005). The binding sites for FoxA1 are enriched in the nER binding regions of promoters of many genes. Small interfering RNA-mediated knockdown of FoxA1 blocks the transcription of other estrogen regulated genes, namely TFF-1 and vitellogenin-B1. These observations reveal an important aspect of the mode of action of E2: induction of transcription factors via the nER, then modulation of subsequent nER action.

Cellular signaling pathways can also modulate nER actions. Different kinases, such as PKA (Chen et al., 1999), mitogen activated protein kinase (MAPK) (Tang et al., 2004) and cyclin A-CDK2 (Rogatsky et al., 1999) are induced by extracellular signals (e.g. growth factors) which leads to phosphorylation of several N-terminal residues of ERα, for example, serines 104, 106, 118 and 167 (Lannigan, 2003). The phosphorylation of the serine residues of nER modulates receptor functions, including nER downregulation by the ubiquitin–proteasome pathway (Marsaud et al., 2003), nuclear localization of nER (Lee and Bai, 2002), nER dimerization (Chen et al., 1999), and transcriptional activity (Ali et al., 1993; Le Goff et al., 1994). Besides targeting nER, signaling pathways can also exert their effects on nER actions through the coregulators. For example,
mutation of the ERK2-responsive phosphorylation site on GRIP-1 inhibits the ability of this coactivator to enhance ERα transcriptional activity stimulated by E2 in human HeLa cells (Lopez et al., 2001). Kinase-mediated signaling pathways most likely serve to induce differential activation and recruitment of nuclear receptors and coregulators, which will modulate gene expression in a cell-specific manner (McKenna and O'Malley, 2002; Smith and O'Malley, 2004; Wu et al., 2005).

The nER can also regulate gene expression without binding directly to DNA. Indeed, many promoters of E2 target genes have no consensus ERE. Rather, nER is assumed to act through specific protein–protein interactions with other classes of transcriptional factors to affect gene transcription. Best studied is the ERα–Sp1 interaction which induces expression of several genes, including E2F1 (Wang et al., 1999), LDL-R (Li et al., 2001), c-fos (Duan et al., 1998) and cyclin D1 (Castro-Rivera et al., 2001). Moreover, interactions between nER and AP-1 proteins (Fos and Jun) increase transcription of ovalbumin (Gaub et al., 1990), IGF-I (Umayahara et al., 1994), collagenase (Webb et al., 1995) and cyclin D1 (Sabbah et al., 1999; Liu et al., 2002), whereas ER-NFκB-C/EBP interaction decreases the expression of interleukin-6 gene (Stein and Yang, 1995).

## 3. Membrane receptor-mediated actions of E2

In addition to the classical nuclear action of E2, rapid membrane-initiated actions have been observed since the late 1960s (Lincoln, 1967; Dufy et al., 1976; Pietras and Szego, 1977; Nakhla et al., 1994; Watters et al., 1997; Kelly and Levin, 2001). E2 exposure can rapidly induce activation of many protein kinases and modulate ion fluxes (i.e. Ca²⁺, K⁺) across the plasma membrane. Since such transient events are not prevented by protein synthesis inhibitors, specific mERs are involved. This is supported by the evidence that treatment with membrane impermeable estrogen, typically E2 conjugated to bovine serum albumin (E2-BSA) in a short time course (seconds to minutes), can mimic the rapid effects of E2 on signal transduction pathways.

### 3.1. Membrane receptors for E2

Mounting evidence suggests that the rapid action of E2 involves an nER acting at the level of the plasma membrane. Using antibodies directed against different epitopes of nERα, several labs have demonstrated its localization in the region of the plasma membrane (Pappas et al., 1995; Norfleet et al., 1999). The data from ERα- and ERβ-knockout (ERKO) mice strongly support a critical role of classical ERs in the rapid action of estrogen (Abraham et al., 2004). Furthermore, ERα has been shown to be translocated to the plasma membrane; two important adaptor proteins, Shc (Src-homology and collagen homology) and IGF-1 (insulin-like growth factor 1 receptor) are involved (Song et al., 2004; Zhang et al., 2004). Using a yeast two-hybrid system, Lu et al. (2004) identified another important protein, striatin, which acts as a molecular anchor for ERα in the plasma membrane. However, other peculiar ER isoforms located at the plasma membrane which are different from the ERα or ERβ also likely exist. Some cell types that do not express either ERα or ERβ can still exhibit rapid responses to E2. For example, mouse pancreatic β cells exhibit rapid membrane-mediated non-genomic responses to estrogens and xenoestrogens yet these cells are immunonegative for membrane-localized classical nERs (Nadal et al., 2000). Recently, Thomas et al. (2005) has shown that a G-protein-coupled receptor (GPCR30) has all the binding and signaling characteristics of a distinct mER in the SKBR3 breast cancer cell line that does not express either ERα or ERβ. This is further supported by Revankar et al. (2005) who examined numerous cell lines. However, in contrast with the plasma membrane location reported previously (Thomas et al., 2005), GPCR30 was localized at the endoplasmic reticulum membranes of COS7 monkey kidney cells transfected with GPCR30 (Revankar et al., 2005). While estrogen signaling in the endoplasmic reticulum would represent a unique mechanism, this is a preliminary observation requiring substantiation (Hewitt et al., 2005b). It is possible that GPCR30 binding of E2 in the endoplasmic reticulum represents binding to newly synthesized GPCR30 in the process of being exported to the plasma membrane (Hewitt et al., 2005b).

### 3.2. Signaling pathways activated by mER

Various signaling pathways are potentially activated by binding of E2 to membrane ERs. These include Ca²⁺ flux (Improta-Brears et al., 1999), cAMP (Nakhla et al., 1994; Watters and Dorsa, 1998), MAPK (Watters et al., 1997; Wade and Dorsa, 2003), PKA (Lagrange et al., 1997), PKC (Qiu et al., 2003), PI3K (Simoncini et al., 2000; Alexaki et al., 2004), and Src kinase (Kennedy et al., 2005). These activating events can be classified into three main signaling pathways, the Ras-Raf-MEK-MAPK, Src-PI3K-Akt-eNOS, and PLC-PKC-cAMP-PKA modules (Fig. 1), though there are numerous potential interactions among these pathways.

MAPK activation upon E2 or E2-BSA exposure has been described in breast cancer cells (Migliaccio et al., 1996), endothelial cells (Russell et al., 2000; Klinge et al., 2005) and adipocytes (Dos Santos et al., 2002). MAPK is activated by phosphorylation on specific threonine and tyrosine residues by MAPK kinases (MEKs). MEKs are themselves activated by several kinases such as the Raf proteins, which in turn are regulated by Ras family members. The binding of mER with E2 can induce the activation of receptor tyrosine kinase (RTK) such as EGF and IGF-1 receptors, which transmit signals through protein complexes including adaptor protein Shc, Grb2, and the guanine nucleotide exchange protein Sos, leading to Ras activation (Driggers and Segars, 2002; Zhang et al., 2004). Besides this pathway, MAPK activation can also be modulated by either G protein through a signaling pathway involving non-receptor tyrosine kinase Src and PI3K (Dos Santos et al., 2002), or intracellular calcium which can modulate Ras activation (Improta-Brears et al., 1999; Kupzig et al., 2005).

The Src-PI3K-Akt-eNOS module is a pathway in endothelial cells mediating rapid E2-dependent release of nitric oxide (NO).
D. Zhang, V.L. Trudeau / Comparative Biochemistry and Physiology, Part A 144 (2006) 306–315

utilization of signal pathways may contribute to the cell type-specific E2 action.

### 3.3. mER signaling pathways can modulate non-nER transcription factors

Activated signaling pathways involving MAPK and PKA can influence the phosphorylation state of multiple non-ER transcription factors, which can ultimately lead to changes in transcription of other genes. Therefore, activation of kinase cascades via the mER is an alternative mechanism for E2 to regulate gene expression.

Many transcription factors have been shown to be regulated by mER-dependent signaling pathways. CREB (cAMP-response element-binding) protein is the most studied target. In a hippocampal cell line (Wade and Dorsa, 2003), adipocyte cells (Dos Santos et al., 2002) and colonic carcinoma cells (Hennessy et al., 2005), CREB transcriptional activity can be induced by E2 or E2-BSA through MAPK pathway, independently of PKA pathway. Such activation of CREB induces expression of several genes including c-fos and UCP-2. In contrast, in neuroblastoma cells activation of CREB by mER is mediated through a cAMP-PKA pathway, leading to neurotensin gene expression (Watters and Dorsa, 1998). This may reflect cell-specific activation of the various signal pathways by mER.

Serum response factor (SRF) and ELK1 are also mER-responsive transcription factors, which are involved in regulating c-fos expression (Hennessy et al., 2005; Duan et al., 2001). It should be noted that in human MCF-7 breast cancer cells, SRF can be regulated by either MAPK pathway (Duan et al., 2001) or PI3K pathway (Duan et al., 2002), implying that the different pathways can cooperate to exert actions.

The AP-1 protein is another effector of mER action. Both DNA binding activity and transcriptional activity of AP-1 can be increased by E2 through MAPK pathway (Dos Santos et al., 2002; Bjornstrom and Sjoberg, 2004), which further contributes to regulating expression of the cyclin D1 and collagenase genes (Marino et al., 2002; Bjornstrom and Sjoberg, 2004). Other targets include several members of the Stat family such as Stat1, Stat3 and Stat5 (Kennedy et al., 2005; Bjornstrom and Sjoberg, 2002). In endothelial cells, activation of both Stat3 and Stat5 by E2 was mediated through signaling pathways involving MAPK, PI3K and Src, and function to regulate β-Casein expression (Bjornstrom and Sjoberg, 2002).

Furthermore, a global gene expression group was identified in vascular endothelial cells responding to the PI3K signaling pathway initiated from mER (Pedram et al., 2002). E2 exposure for 40 min rapidly upregulated approximately 250 genes, which was prevented by inhibiting the PI3K pathway with LY294002. It should be noted that several typical genes responsible for mER actions, such as c-fos and cyclin D1, were also shown to be regulated by direct interactions between nER and other transcription factors, including Sp1 and AP-1 (Duan et al., 1998; Castro-Rivera et al., 2001; Sabbah et al., 1999; Liu et al., 2002). Therefore, in future research it will be necessary to
consider both contributions of direct interactions of nERs with other transcription factors, as well as mER signaling, in the regulation of gene expression.

### 3.4. Membrane actions of E2 can modulate its nuclear actions

In addition to the transcription factors discussed in Section 3.3, classical nERs and their coactivators are also possible targets of mER-mediated signaling events, involving PKA or MAPK. Therefore, it is reasonable to propose that the mER has modulatory effects on nER action through kinase cascades. Indeed, it has been long known that E2 treatment can increase phosphorylation state of nERs, and mutation of important phosphorylation sites reduces the transcription activity of nERs (Ali et al., 1993; Le Goff et al., 1994). Also AIB1, one nER coactivator, has been reported to be phosphorylated following E2 exposure in human HEK293 cells and MCF-7 cells (Wu et al., 2004). Multiple cellular signaling pathways, including p38, JNK, and ERK1/2, are involved. RNAi-mediated knockdown of these kinases diminishes the nER-induced expression of endogenous pS2, which implies the critical contribution of mER signaling in nER actions through AIB1. Furthermore, induction of MAPK and PI3K pathways by mER are both necessary and sufficient for the transcription of non-nER regulated genes, but also for the transcription of nER-regulated genes (Accconcia and Marino, 2003). Using a two-pulse paradigm of hormone administration, Vasudevan et al. (2001) demonstrated that rapid E2 action can potentiate slower nER-mediated transcriptional processes in neuroblastoma cells. Moreover, intracellular signaling cascades were shown to be important in such potentiation; inhibition of PKA, PKC, MAPK or PI3K in the first pulse decreased this effect (Kow and Pfaff, 2004).

There may exist another generalized mechanism whereby mER signaling modulates nER action. Rapidly induced genes, such as c-fos and cyclin D1, are known coregulators for nuclear receptor action (Kovacs, 1998; Fu et al., 2004; Burd et al., 2005). It is hypothesized that these inducible coregulators or third messengers (Kovacs, 1998) in the rapid mER pathway modulate slower nuclear actions of E2. While this idea requires experimental substantiation, there is evidence that early events affect later E2 actions. For example, early induction of FoxA1 through the nER defines a responsive gene group of later nER action (Laganiere et al., 2005; Carroll et al., 2005).

### 3.5. A dynamic integrative model for mER and nER signaling

We propose a model integrating both early and late mER and nER signaling which is depicted in Fig. 1. E2 initiates membrane actions and nuclear actions through binding to a membrane receptor (GPCR or classical ER) and a nuclear receptor, respectively. Three main signaling pathways, the Ras-Raf-MEK-MAPK (Driiggers and Segars, 2002), Src-PI3K-Akt-eNOS (Segars and Driggers, 2002) and PLC-PKC-cAMP-PKA modules (Malyala et al., 2005), are rapidly activated during membrane actions. Following activation of these pathways a series of transcription factors (e.g. CREB and AP1) are induced.

This can modulate expression of some genes that do not contain the consensus ERE in the promoter region. At the same time, mER initiated signaling exerts a modulatory effect on nER action by interacting with nER and coactivators. Furthermore, inducible expression of third messengers (e.g. c-fos, cyclin D1, and FoxA1) is a possible mechanism linking the earlier and later estrogen actions.

### 4. Membrane receptor-mediated actions of other hormones

In addition to established nuclear receptor mechanisms, there is also evidence for membrane receptor-mediated processes for thyroid hormone (TH), progesterone (P4), androgens, glucocorticoids, vitamin D3 and aldosterone (Falkenstein et al., 2000). Common rapid effects include intracellular ion flux and activation of a series of protein kinases such as MAPK, PI3K, and PKA. Membrane receptors for some of these hormones have been identified. For example, a classical nuclear receptor mediates the membrane actions of aldosterone in rat mesenteric resistance vessels (Michea et al., 2005), while integrin αvβ3 may mediate the membrane actions of TH in African green monkey CV-1 fibroblast cell line (Bergh et al., 2005). The membrane receptor for progesterone (mPR) in spotted sea trout ovaries was the first unequivocal steroid G-protein-coupled receptor identified (Zhu et al., 2003). However, the classical nPR was also localized at the plasma membrane and contributes to rapid MAPK activation by progesterone in Xenopus laevis oocytes (Bayaa et al., 2000). Thus, both classical nuclear receptors and novel membrane-specific receptors mediate the membrane actions of both E2 and P4. It is reasonable to speculate that this is also true for the other hormones with identified “classical” receptors in the nuclear receptor superfamily.

The modulatory effects of membrane receptor activation on nuclear receptor actions observed for E2 likely exist for other hormones. Fairet al. (2005) showed that mPR-mediated rapid signaling can regulate the expression of genes important for breast cancer cell growth independently of nPR, and can also enhance nPR actions through phosphorylation events. In the case of aldosterone action, the nuclear mineralocorticoid receptor can be rapidly phosphorylated on serine and threonine residues following treatments with aldosterone or aldosterone-BSA, while its nuclear transcriptional activity can be inhibited through blocking the PKC pathway as demonstrated by suppression of aldosterone-induced Na+/K+/ATPase mRNA in the RCCD(2) rat cortical collecting duct cell line (Le Moellic et al., 2004). Thyroid hormone exposure of 293 T cells leads to nuclear TR acetylation via a membrane receptor initiated MAPK pathway (Lin et al., 2005). Thus, the modulatory effects of rapid membrane actions on slower nuclear actions of hormones via signaling pathways are common to several hormones.

Induction of cyclin D1 and c-fos may also be common to membrane steroid receptor actions. Cyclin D1 is increased by progesterone exposure via the MAPK pathway in several human breast cancer cell lines (Fairet al., 2005), and also following triiodothyronine (T3) exposure in mouse hepatocytes (Pibiri et al., 2001). Because of their distinctive function
in regulating nuclear receptor action of hormones and their inducible expression in a non-hormone-specific manner, these immediate genes are expected to be third messengers to create extended circuitries of hormone action. Collectively, these data suggest that like E2 (Fig. 1), other hormone may have a similar mode of action involving an integration of rapid membrane and slower nuclear hormone receptor actions through kinases and induced third messengers (i.e. cyclin D1).

5. Crosstalk between various hormones through induced signal pathways

Given that signal transduction pathways such as MAPK and PKA are commonly utilized by different steroid hormones to link membrane actions and downstream nuclear actions, it is possible that one hormone-responsive transcriptional complex could be modulated by signaling pathways initiated from membrane receptors for a different hormone.

One study has shown that the Src/Shc/ERK signal pathway can be activated by either estrogen or androgen (DHT, 5α-dihydrotestosterone) in mammal osteoblasts, osteocytes, embryonic fibroblasts and HeLa cells (Kousteni et al., 2001). Furthermore, several transcription factors, including Elk-1, CCAAT enhancer binding protein-beta (C/EBPβ), and CREB, or c-Jun/c-Fos can be activated by Src/Shc/ERK pathway which are initiated from extranuclear actions of the ER or AR (Kousteni et al., 2003). This is one possible crosstalk model that illustrates how different hormones can regulate the same downstream TF via the same signal pathway (Fig. 2a).

Interaction between TH and E2 signaling represents another possible crosstalk model (Fig. 2b). Thyroid hormone (T3 and T4) has an estrogen-like effect in breast cancer cells, inducing cell proliferation through p53 levels and hyperphosphorylation of the TF pRb (Dinda et al., 2002). Cotreatment with an ER antagonist prevented this effect of TH, suggesting ER involvement. Application of either TH or membrane impermeable agarose-TH leads to phosphorylation of serines 167 and 118 of ERα, implicating the involvement of a putative membrane TH receptor (mTR) (Dinda et al., 2002); the MAPK pathway may mediate this crosstalk event since an inhibitor of ERK1/2 phosphorylation restrained this process (Tang et al., 2004; Zhao et al., 2005). Thus, TH can affect nER action via a mTR-mediated pathway. This model is similar to the crosstalk between epidermal growth factor (EGF) and E2 in breast cancer cells. In addition to targeting nER, signaling from the EGF receptor can also modulate nER action by activating the ER coactivator protein AIB1 (Osborne and Schiff, 2003) (Fig. 2c).

The regulatory effect of gonadotropin-releasing hormone (GnRH) on nER action in the mouse LbT2 gonadotrope cells is another example of crosstalk (Luo et al., 2005) (Fig. 2d). In this process, the GnRH signaling pathway does not regulate nER directly. Rather, GnRH induces the expression of ubiquitin-conjugating enzyme 4 (ubc4), which subsequently promotes nER ubiquitylation. These examples all demonstrate that the nER actions can be modulated by signaling pathways originating from both steroid and peptide hormone-membrane receptor binding.

6. Conclusions and perspectives

The discovery of mER-mediated actions greatly expands our understanding of E2 action. The classical mechanism in which E2 regulates gene expression is through interactions with coactivators/corepressors, dimerization of nERs and subsequent binding to specific EREs in target genes (Gruber et al., 2004). In contrast to this mechanism, membrane receptor binding of E2 initiates various signaling pathways and activates other transcription factors that can lead to transcription of some genes without EREs. Also membrane ER-mediated actions of E2 exert a modulatory effect on nER actions through signaling

Fig. 2. Crosstalk models between E2 and other hormones. (a) The same signaling pathway (MAPK) is utilized by E2 or androgen to activate CREB protein in mammal osteoblasts, osteocytes, embryonic fibroblasts and HeLa cells (Kousteni et al., 2001, 2003). (b) Similar to E2, thyroid hormone regulates nER action through MAPK pathway in breast cancer cells (Dinda et al., 2002; Tang et al., 2004; Zhao et al., 2005). (c) Membrane EGF receptor can regulate nER action through targeting both nER and its coactivator, AIB1 in breast cancer cells (Osborne and Schiff, 2003). (d) GnRH regulate nER action indirectly through inducing UBC4 expression in the mouse LbT2 gonadotrope cells (Luo et al., 2005). In the figure the upper line represents membrane structure, while the lower double line represents a gene promoter target for binding of the transcriptional complex. For details refer to main text and references. Abbreviations: mAR, membrane receptor for DHT; GnRHR, membrane receptor GnRH; Sf-1, steroidogenic factor 1; Pitx1, Pituitary homeobox 1. For other abbreviations not defined here refer to main text.

pathways targeting nER and coactivators, and increasing expression of immediately inducible genes (i.e., cyclin D1 or c-fos). This pattern of membrane receptor modulation of nuclear receptor action is likely to exist for other hormones. Furthermore, steroid hormones and other hormones acting through other members of the nuclear steroid hormone receptor superfamily (i.e., TH) also activate many of the same intracellular signaling cascades which provide an extensive crosstalk network between diverse hormones.

A model integrating membrane receptor and nuclear receptor pathways for E2 action (Fig. 1) provides a framework to investigate the diverse actions of endocrine disrupting chemicals (EDCs). For example, xenoestrogens, the structurally diverse group of compounds which can mimic or antagonize the physiological effects of E2 through the nER (Petit et al., 1997), may also activate signaling pathways initiated at the plasma membrane (Bulayeva and Watson, 2004; Canesi et al., 2004). Considerable research remains to substantiate the membrane receptor–nuclear receptor interaction hypothesis. The development of specific small molecular weight agonists and antagonists for membrane steroid receptors with no activity at the nuclear receptor remains a challenge. Global expression techniques such as microarrays and proteomics with associated bioinformatic approaches will be especially useful in determining the relative roles of the membrane receptor and nuclear receptor pathways.

## Acknowledgements

The financial support of the University of Ottawa International Scholarship program (to D.Z.) and the NSERC Discovery and Strategic programs (to V.L.T.) is acknowledged with appreciation. The helpful suggestions of Chris Martyniuk, Vicki Marlatt and Susanna Wiens are appreciated.

## References

Abraham, I.M., Todman, M.G., Korach, K.S., Herbison, A.E., 2004. Critical in vivo roles for classical estrogen receptors in rapid estrogen actions on intracellular signaling in mouse brain. Endocrinology 145, 3055–3061.

Acconcia, F., Marino, M., 2003. Synergism between genomic and non genomic estrogen action mechanisms. IUBMB Life 55, 145–150.

Alexaki, V.I., Charalampopoulos, I., Kampa, M., Vassalou, H., Theodoropoulos, P., Stathopoulos, E.N., Hatzoglou, A., Gravanis, A., Castanas, E., 2004. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J. 18, 1594–1596.

Ali, S., Metzger, D., Bornert, J.M., Chambon, P., 1993. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J. 12, 1153–1160.

Ansonoff, M.A., Etgen, A.M., 1998. Estradiol elevates protein kinase C catalytic activity in the preoptic area of female rats. Endocrinology 139, 3050–3056.

Bayaa, M., Booth, R.A., Sheng, Y., Liu, X.J., 2000. The classical progesterone receptor mediates Xenopus oocyte maturation through a nongenomic mechanism. Proc. Natl. Acad. Sci. U. S. A. 97, 12607–12612.

Bergh, J.J., Lin, H.Y., Lansing, L., Mohamed, S.N., Davis, F.B., Mousa, S., Davis, P.J., 2005. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146, 2864–2871.

Bjornstrom, L., Sjoberg, M., 2002. Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol. Endocrinol. 16, 2202–2214.

Bjornstrom, L., Sjoberg, M., 2004. Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl. Recept. 2, 3.

Bulayeva, N.N., Watson, C.S., 2004. Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ. Health Perspect. 112, 1481–1487.

Bulun, S.E., Zeitoun, K.M., Takayama, K., Sasano, H., 2000. Estrogen biosynthesis in endometriosis, molecular basis and clinical relevance. J. Mol. Endocrinol. 25, 35–42.

Burd, C.J., Petre, C.E., Moghadam, H., Wilson, E.M., Knudsen, K.E., 2005. Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. Mol. Endocrinol. 19, 607–620.

Canesi, L., Lorusso, L.C., Ciacci, C., Betti, M., Zampini, M., Gallo, G., 2004. Environmental estrogens can affect the function of mussel hemocytes through rapid modulation of kinase pathways. Gen. Comp. Endocrinol. 138, 58–69.

Carroll, J.S., Liu, X.S., Brodsky, A.S., Li, W., Meyer, C.A., Szary, A.J., Eckhoute, J., Shao, W., Hestermann, E.V., Geistlinger, T.R., Fox, E.A., Silver, P.A., Brown, M., 2005. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33–43.

Castro-Rivera, E., Samudio, I., Safe, S., 2001. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 276, 30853–30861.

Charlier, T.D., Ball, G.F., Balthazart, J., 2005. Inhibition of steroid receptor coactivator-1 blocks estrogen and androgen action on male sex behavior and associated brain plasticity. J. Neurosci. 25, 906–913.

Chen, D., Pace, P.E., Coombes, R.C., Ali, S., 1999. Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol. Cell. Biol. 19, 1002–1015.

Couse, J.F., Korach, K.S., 2001. Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. Ann. N.Y. Acad. Sci. 948, 1–8.

Couse, J.F., Lindzey, J., Grandien, K., Gustafsson, J.A., Korach, K.S., 1997. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138, 4613–4621.

Cowley, S.M., Hoare, S., Mosselman, S., Parker, M.G., 1997. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 272, 19858–19862.

Dinda, S., Sanchez, A., Moudgil, V., 2002. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21, 761–768.

Dos Santos, E.G., Dieudonne, M.N., Pecquery, R., Le Moal, V., Giudicelli, Y., Lacasa, D., 2002. Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes. Endocrinology 143, 930–940.

Draggers, P.H., Segars, J.H., 2002. Estrogen action and cytoplasmic signaling pathways: Part II. The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol. Metab. 13, 422–427.

Duan, R., Porter, W., Safe, S., 1998. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139, 1981–1990.

Duan, R., Xie, W., Burghardt, R.C., Safe, S., 2001. Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J. Biol. Chem. 276, 11590–11598.

Duan, R., Xie, W., Li, X., McDougal, A., Safe, S., 2002. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 294, 384–394.

Dufy, B., Partouche, C., Poulain, D., Dufy-Barbe, L., Vincent, J.D., 1976. Effects of estrogen on the electrical activity of identified hypothalamic units. Neuroendocrinology 22, 38–47.

Faire, E., Skildum, A., Pierson-Mullany, L., Lange, C.A., 2005. Integration of progesterone receptor mediated rapid signaling and nuclear actions in breast

cancer cell models, role of mitogen-activated protein kinases and cell cycle regulators. Steroids 70, 418–426.

Falkenstein, E., Tillmann, H.C., Christ, M., Feuring, M., Wehling, M., 2000. Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. Pharmacol. Rev. 52, 513–556.

Fu, M., Wang, C., Li, Z., Sakamaki, T., Pestell, R.G., 2004. Minireview, Cyclin D1, normal and abnormal functions. Endocrinology 145, 5439–5447.

Gaub, M.P., Bellard, M., Scheuer, I., Chambon, P., Sassone-Corsi, P., 1990. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell. 63, 1267–1276.

Gruber, C.J., Gruber, D.M., Gruber, I.M., Wieser, F., Huber, J.C., 2004. Anatomy of the estrogen response element. Trends Endocrinol. Metab. 15, 73–78.

Gu, Q., Moss, R.L., 1996. 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J. Neurosci. 16, 3620–3629.

Haynes, M.P., Li, L., Sinha, D., Russell, K.S., Hisamoto, K., Baron, R., Collinge, M., Sessa, W.C., Bender, J.R., 2003. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J. Biol. Chem. 278, 2118–2123.

Hennessy, B.A., Harvey, B.J., Healy, V., 2005. 17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells. Mol. Cell. Endocrinol. 229, 39–47.

Hess, R.A., 2003. Estrogen in the adult male reproductive tract: a review. Reprod. Biol. Endocrinol. 1, 52.

Hewitt, S.C., Harrell, J.C., Korach, K.S., 2005a. Lessons in estrogen biology from knockout and transgenic animals. Annu. Rev. Physiol. 67, 285–308.

Hewitt, S.C., Deroo, B.J., Korach, K.S., 2005b. A new mediator for an old hormone? Science 307, 1572–1573.

Impronta-Brears, T., Whorton, A.R., Codazzi, F., York, J.D., Meyer, T., McDonnell, D.P., 1999. Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc. Natl. Acad. Sci. U. S. A. 96, 4686–4691.

Kelly, M.J., Loose, M.D., Ronnekleiv, O.K., 1992. Estrogen suppresses mu-opioid- and GABAB-mediated hyperpolarization of hypothalamic arcuate neurons. J. Neurosci. 12, 2745–2750.

Kelly, M.J., Levin, E.R., 2001. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab. 12, 152–156.

Kennedy, A.M., Shogren, K.L., Zhang, M., Turner, R.T., Spelsberg, T.C., Maran, A., 2005. 17beta-estradiol-dependent activation of signal transducer and activator of transcription-1 in human fetal osteoblasts is dependent on Src kinase activity. Endocrinology 146, 201–207.

Klinge, C.M., Blankenship, K.A., Risinger, K.E., Bhatnagar, S., Noisin, E.L., Sumanasekera, W.K., Zhao, L., Brey, D.M., Keynton, R.S., 2005. Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptor α and β in endothelial cells. J. Biol. Chem. 280, 7460–7468.

Kousteni, S., Bellido, T., Plotkin, L.I., O’Brien, C.A., Bodenner, D.L., Han, L., Han, K., DiGregorio, G.B., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Roberson, P.K., Weinstein, R.S., Jilka, R.L., Manolagas, S.C., 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors, dissociation from transcriptional activity. Cell 104, 719–730.

Kousteni, S., Han, L., Chen, J.R., Almeida, M., Plotkin, L.I., Bellido, T., Manolagas, S.C., 2003. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J. Clin. Invest. 111, 1651–1664.

Kovacs, K.J., 1998. c-Fos as a transcription factor, a stressful (re)view from a functional map. Neurochem. Int. 33, 287–297.

Kow, L.M., Pfaff, D.W., 2004. The membrane actions of estrogens can potentiate their lordosis behavior-facilitating genomic actions. Proc. Natl. Acad. Sci. U. S. A. 101, 12354–12357.

Kupzig, S., Walker, S.A., Cullen, P.J., 2005. The frequencies of calcium oscillations are optimized for efficient calcium-mediated activation of Ras and the ERK/MAPK cascade. Proc. Natl. Acad. Sci. U. S. A. 102, 7577–7582.

Laganiere, J., Deblois, G., Lefebvre, C., Bataille, A.R., Robert, F., Giguere, V., 2005. Location analysis of estrogen receptor {alpha} target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U. S. A. 102, 11651–11656.


Lagrange, A.H., Ronnekleiv, O.K., Kelly, M.J., 1997. Modulation of G protein-coupled receptors by an estrogen receptor that activates protein kinase A. Mol. Pharmacol. 51, 605–612.

Lannigan, D.A., 2003. Estrogen receptor phosphorylation. Steroids 68, 1–9.

Le Goff, P., Montano, M.M., Schodin, D.J., Katzenellenbogen, B.S., 1994. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem. 269, 4458–4466.

Le Moellic, C., Ouvrard-Pascaud, A., Capurro, C., Cluzeaud, F., Fay, M., Jaisser, F., Farman, N., Blot-Chabaud, M., 2004. Early nongenomic events in aldosterone action in renal collecting duct cells, PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. J. Am. Soc. Nephrol. 15, 1145–1160.

Lee, H., Bai, W., 2002. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol. 22, 5835–5845.

Li, C., Briggs, M.R., Ahlborn, T.E., Kraemer, F.B., Liu, J., 2001. Requirement of Sp1 and estrogen receptor alpha interaction in 17beta-estradiol-mediated transcriptional activation of the low density lipoprotein receptor gene expression. Endocrinology 142, 1546–1553.

Lin, H.Y., Hopkins, R., Cao, H.J., Tang, H.Y., Alexander, C., Davis, F.B., Davis, P.J., 2005. Acetylation of nuclear hormone receptor superfamily members, thyroid hormone causes acetylation of its own receptor by a mitogen-activated protein kinase-dependent mechanism. Steroids 70, 444–449.

Liu, M.M., Albanese, C., Anderson, C.M., Hilty, K., Webb, P., Uht, R.M., Price Jr., R.H., Pestell, R.G., Kushner, P.J., 2002. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 277, 24353–24360.

Lincoln, D.W., 1967. Unit activity in the hypothalamus, septum and preoptic area of the rat, characteristics of spontaneous activity and the effect of oestrogen. J. Endocrinol. 37, 177–189.

Lopez, G.N., Turck, C.W., Schaufele, F., Stallcup, M.P., Kushner, P.J., 2001. Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 co-activator activity. J. Biol. Chem. 276, 22177–22182.

Lu, Q., Pallas, D.C., Surks, H.K., Baur, W.E., Mendelsohn, M.E., Karas, R.H., 2004. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. U. S. A. 101, 17126–17131.

Luo, M., Koh, M., Feng, J., Wu, Q., Melamed, P., 2005. Cross talk in hormonally regulated gene transcription through induction of estrogen receptor ubiquitylation. Mol. Cell. Biol. 25, 7386–7398.

Malyala, A., Kelly, M.J., Ronnekleiv, O.K., 2005. Estrogen modulation of hypothalamic neurons, activation of multiple signaling pathways and gene expression changes. Steroids 70, 397–406.

Marino, M., Acconcia, F., Bresciani, F., Weisz, A., Trentalance, A., 2002. Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells. Mol. Biol. Cell 13, 3720–3729.

Marsaud, V., Gougelet, A., Maillard, S., Renoir, J.M., 2003. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 17, 2013–2027.

Martyniuk, C.J., Gallant, N.S., Marlatt, V.L., Wiens, S.C., Woodhouse, A.J., Trudeau, V.L., in press. Current perspectives on estrogen action and estrogen receptors in teleost fishes. In Fish Endocrinology. Book Chapter. Editor, Giacomo Zaccone.

McKenna, N.J., O’Malley, B.W., 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465–474.

Menuet, A., Pellegrini, E., Anglade, I., Blaise, O., Laudet, V., Kah, O., Pakdel, F., 2002. Molecular characterization of three estrogen receptor forms in zebrafish, binding characteristics, transactivation properties, and tissue distributions. Biol. Reprod. 66, 1881–1892.

Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M., Gannon, F., 2003. Estrogen receptor-alpha directs ordered, cyclical, and

combinatorial recruitment of cofactors on a natural target promoter. Cell 115, 751–763.

Michea, L., Delpiano, A.M., Hitschfeld, C., Lobos, L., Lavandero, S., Marusic, E.T., 2005. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 46, 973–980.

Migliaccio, A., Di Domenico, M., Castoria, G., de Falco, A., Bontempo, P., Nola, E., Auricchio, F., 1996. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15, 1292–1300.

Molenda, H.A., Griffin, A.L., Auger, A.P., McCarthy, M.M., Tetel, M.J., 2002. Nuclear receptor coactivators modulate hormone-dependent gene expression in brain and female reproductive behavior in rats. Endocrinology 143, 436–444.

Nadal, A., Ropero, A.B., Laribi, O., Maillet, M., Fuentes, E., Soria, B., 2000. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor α and estrogen receptor β. Proc. Natl. Acad. Sci. U. S. A. 97, 11603–11608.

Nakhla, A.M., Khan, M.S., Romas, N.P., Rosner, W., 1994. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc. Natl. Acad. Sci. U. S. A. 91, 5402–5405.

Norfleet, A.M., Thomas, M.L., Gametchu, B., Watson, C.S., 1999. Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme-linked immunocytochemistry. Endocrinology 140, 3805–3814.

Osborne, C.K., Schiff, R., 2003. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12, 362–367.

Pappas, T.C., Gametchu, B., Watson, C.S., 1995. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 9, 404–410.

Pedram, A., Razandi, M., Aitkenhead, M., Hughes, C.C., Levin, E.R., 2002. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem. 277, 50768–50775.

Petit, F., Le Goff, P., Cravedi, J.P., Valotaire, Y., Pakdel, F., 1997. Two complementary bioassays for screening the estrogenic potency of xenobiotics, recombinant yeast for trout estrogen receptor and trout hepatocyte cultures. J. Mol. Endocrinol. 9, 321–335.

Pibiri, M., Cossu, C., Simbula, G., Menegazzi, M., Shinozuka, H., Columbano, A., 2001. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J. 15, 1006–1013.

Picotto, G., Massheimer, V., Boland, R., 1996. Acute stimulation of intestinal cell calcium influx induced by 17 beta-estradiol via the cAMP messenger system. Mol. Cell. Endocrinol. 119, 129–134.

Picotto, G., Vazquez, G., Boland, R., 1999. 17beta-oestradiol increases intracellular Ca2+ concentration in rat enterocytes. Potential role of phospholipase C-dependent store-operated Ca2+ influx. Biochem. J. 339, 71–77.

Pietras, R.J., Szego, C.M., 1977. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265, 69–72.

Qiu, J., Bosch, M.A., Tobias, S.C., Grandy, D.K., Scanlan, T.S., Ronnekleiv, O.K., Kelly, M.J., 2003. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J. Neurosci. 23, 9529–9540.

Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B., Prossnitz, E.R., 2005. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625–1630.

Russell, K.S., Haynes, M.P., Sinha, D., Clerisme, E., Bender, J.R., 2000. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U. S. A. 97, 5930–5935.

Rogatsky, I., Trowbridge, J.M., Garabedian, M.J., 1999. Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem. 274, 22296–22302.

Sabbah, M., Courilleau, D., Mester, J., Redeuilh, G., 1999. Estrogen induction of the cyclin D1 promoter, involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. U. S. A. 96, 11217–11222.

Segars, J.H., Driggers, P.H., 2002. Estrogen action and cytoplasmic signaling cascades: Part I. Membrane-associated signaling complexes. Trends Endocrinol. Metab. 13, 349–354.

Shughruie, P.J., Lane, M.V., Merchenthaler, I., 1997. Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J. Comp. Neurol. 388, 507–525.

Shughruie, P.J., Lane, M.V., Scrimo, P.J., Merchenthaler, I., 1998. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 63, 498–504.

Simoncini, T., Hafezi-Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W., Liao, J.K., 2000. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407, 538–541.

Smith, C.L., O'Malley, B.W., 2004. Coregulator function, a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45–71.

Song, R.X., Barnes, C.J., Zhang, Z., Bao, Y., Kumar, R., Santen, R.J., 2004. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor α to the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 101, 2076–2081.

Stein, B., Yang, M.X., 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol. Cell. Biol. 15, 4971–4979.

Tang, H.Y., Lin, H.Y., Zhang, S., Davis, F.B., Davis, P.J., 2004. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 145, 3265–3272.

Thomas, P., Pang, Y., Filardo, E.J., Dong, J., 2005. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146, 624–632.

Thornton, J.W., Need, E., Crews, D., 2003. Resurrecting the ancestral steroid receptor, ancient origin of estrogen signaling. Science 301, 1714–1717.

Tsai, M.J., O'Malley, B.W., 1994. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451–486.

Umayahara, Y., Kawamori, R., Watada, H., Imano, E., Iwama, N., Morishima, T., Yamasaki, Y., Kajimoto, Y., Kamada, T., 1994. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem. 269, 16433–16442.

Vasudevan, N., Kow, L.M., Pfaff, D.W., 2001. Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line. Proc. Natl. Acad. Sci. U. S. A. 98, 12267–12271.

Wade, C.B., Dorsa, D.M., 2003. Estrogen activation of cyclic adenosine 5′-monophosphate response element-mediated transcription requires the extracellularly regulated kinase/mitogen-activated protein kinase pathway. Endocrinology 144, 832–838.

Wang, W., Dong, L., Saville, B., Safe, S., 1999. Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol. 13, 1373–1387.

Watters, J.J., Dorsa, D.M., 1998. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. J. Neurosci. 18, 6672–6680.

Watters, J.J., Campbell, J.S., Cunningham, M.J., Krebs, E.G., Dorsa, D.M., 1997. Rapid membrane effects of steroids in neuroblastoma cells, effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription. Endocrinology 138, 4030–4033.

Webb, P., Lopez, G.N., Uht, R.M., Kushner, P.J., 1995. Tamoxifen activation of the estrogen receptor/AP-1 pathway, potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9, 443–456.

Wu, R.C., Qin, J., Yi, P., Wong, J., Tsai, S.Y., Tsai, M.J., O'Malley, B.W., 2004. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol. Cell 15, 937–949.

Wu, R.C., Smith, C.L., O'Malley, B.W., 2005. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 26, 393–399.

Ylikomi, T., Wurtz, J.M., Syvala, H., Passinen, S., Pekki, A., Haverinen, M., Blauer, M., Tuohimaa, P., Gronemeyer, H., 1998. Reappraisal of the role of

heat shock proteins as regulators of steroid receptor activity. Crit. Rev. Biochem. Mol. Biol. 33, 437–466.

Zhang, Z., Kumar, R., Santen, R., Song, R.X., 2004. The role of adapter protein Shc in estrogen non-genomic action. Steroid 69, 523–529.

Zhao, X., Lorenc, H., Stephenson, H., Wang, Y.J., Witherspoon, D., Katzenellenbogen, B., Pfaff, D., Vasudevan, N., 2005. Thyroid hormone can increase estrogen-mediated transcription from a consensus estrogen

response element in neuroblastoma cells. Proc. Natl. Acad. Sci. U. S. A. 102, 4890–4895.

Zhu, Y., Rice, C.D., Pang, Y., Pace, M., Thomas, P., 2003. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc. Natl. Acad. Sci. U. S. A. 100, 2231–2236.
